Skip to content

TKA Melatonin and Sleep Quality

Association Between Melatonin Use and Improved Sleep Quality After Total Knee Arthroplasty: A Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05332717
Enrollment
176
Registered
2022-04-18
Start date
2022-01-10
Completion date
2022-04-30
Last updated
2023-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Knee, Sleep Initiation and Maintenance Disorders

Keywords

Melatonin, Arthroplasty, Knee, Sleep

Brief summary

This randomized controlled trial (RCT) will compare the effects of melatonin vs. placebo in patients undergoing primary total knee arthroplasty (TKA). This RCT aims to study the effects melatonin has on sleep quality after TKA. Patients will be blinded to their respective groups and will be instructed to take either 5mg melatonin or a placebo pill (Vitamin C) for 6 weeks postoperative. Sleep quality surveys will be administered preoperatively and post-operative week 6, 90-days and 1 year. Poor sleep quality is a common issue faced by patients undergoing TKA. The goal of this study is see if melatonin can improve postoperative sleep quality, and if so, does improved sleep quality correlate to improvements in other postoperative outcomes.

Detailed description

This study will compare postoperative sleep quality in two groups of patients undergoing primary total knee arthroplasty (TKA): * Group 1 will take one melatonin (5 mg) tablet nightly, \ 30 minutes before bedtime during the 6 week postoperative period * Group 2 will take one placebo (5 mg Vitamin C) tablet nightly, \ 30 minutes before bedtime during the 6 week postoperative period The primary outcome will be sleep quality at 6 weeks. Sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI). The survey will be administered preoperatively, 6-weeks, 90-days and 1 year postoperatively. Preoperative surveys will be completed in-person, on-site by study participants. All postoperative surveys will be distributed via email. Secondary outcomes include: * (KOOS Jr, LEAS, VR-12, VAS) administered preoperatively, at 6-weeks, 90-days and 1-year post-operatively. * Total opioids prescribed in first 3 months postoperative will be collected using iStop * Frequency of CMS defined surgicalcomplications in the first 90-days after primary TKA. * Adverse events of Melatonin during the first 6 weeks (collected via email survey sent to participants once per week, for the first 6 weeks) * Study medication compliance at 6 weeks (collected via email survey sent to participants once per week, for the first 6 weeks)

Interventions

DIETARY_SUPPLEMENTMelatonin 5 mg

Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.

DIETARY_SUPPLEMENTPlacebo (Vitamin C)

Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.

Sponsors

Hospital for Special Surgery, New York
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Masking description

Participants will not be informed if they are receiving study drugs or placebo pills. Placebos will be compounded to be identical to treatment drugs in shape, size, color, texture etc.

Intervention model description

This study will compare postoperative sleep quality in two groups of patients undergoing primary total knee arthroplasty (TKA): * Group 1 will take melatonin during the 6 week postoperative period * Group 2 will take a placebo during the 6 week postoperative period

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing primary, unilateral TKA * Primary diagnosis of osteoarthritis (OA) * Aged 18+ * Subject is opioid naive (has not taken opioids during the 6 months prior to surgery) * Subject is not currently taking sleep medication * English speaking * Has working email (for survey purposes)

Exclusion criteria

* Patients with diagnosis other than OA including: Inflammatory arthritis; Post-traumatic OA; Chronic pain; Insomnia\*; Depression\*; Anxiety\*; Any active sleep disorder * Planned contralateral knee or subsequent total joint arthroplasty within 90 days * Any planned surgery within 90 days * Patient taking medication for depression or insomnia or anxiety during the 6 months prior to surgery * Patients with renal or hepatic disorders as these can affect melatonin metabolism * Insomnia, anxiety, and depression will be defined as use of controlled medication for that disorder which will be identified in istop or HSS record of the patient filled in the 6 months prior to surgery

Design outcomes

Primary

MeasureTime frameDescription
Sleep QualityPreoperativelyAssessed based on self-reported data collected using the Pittsburgh Sleep Quality Index (PSQI). Minimum Score: 0; Maximum Score: 21. Higher scores indicate a worse outcome.

Secondary

MeasureTime frameDescription
Knee FunctionPreoperatively, 6-week, 90-day and 1-year follow-upAssessed based on self-reported data collected using the abbreviated Knee Injury and Osteoarthritis Outcome Score (KOOS Jr). Minimum Score: 0; Maximum Score: 28. Higher scores indicate a better outcome.
Overall HealthPreoperatively, 6-week, 90-day and 1-year follow-upAssessed based on self-reported data collected using the Veterans Rand 12 (VR-12) Scale. Minimum Score: 0; Maximum Score: 100. Higher scores indicate a better outcome.
Pain RatingsPreoperatively, 6-week, 90-day and 1-year follow-upAssessed based on self-reported data collected using the Visual Analogue Pain Scale. Minimum Score: 0; Maximum Score: 10. Higher scores indicate a worse outcome.
Lower Extremity ActivityPreoperatively, 6-week, 90-day and 1-year follow-upAssessed based on self-reported data collected using the Lower Extremity Activity Scale (LEAS). Minimum Score: 1; Maximum Score: 18. Higher scores indicate a better outcome.
Quantity of Postoperative Centers for Medicare and Medicaid Services Complications90-day follow-upAssessed using institutional medical record data.
Study Medication ComplianceWeekly (Up to 6 weeks)Assessed based on self-reported data collected via study survey.
Quantity of Adverse Melatonin Medical EventsWeekly (Up to 6 weeks)Assessed based on self-reported data collected via study survey.
Opioids Prescribed90-day follow-upThis will me quantified in morphine milligram equivalents (MMEs). This information will be obtained for each patient using institutionally queried i-Stop data.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026